PGR and neoplasm: Clinicians rely on traditional clinico-pathological, and readily available, tumor markers such as estrogen receptor (ER), progesterone receptor (PR), and human epithelial receptor-2 (HER-2) because they are reliable, inexpensive, and useful for therapeutic decision making.